BGC > Product Search > [4-[(5,6-Diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid | 475085-57-5

Molecular Formula: C25H29N3O3
Molecular Weight: 419.51606

Description :
MRE-269 is an orally available and long-acting prostacyclin receptor agonist prodrug used for the treatment of pulmonary arterial hypertension.

• Molecular Weight :419.5
• Purity :≥98%

Molecular Formula :
C25H29N3O3
Canonical SMILES :
OC(=O)COCCCCN(C(C)C)c1cnc(c2ccccc2)c(n1)c1ccccc1
InChI :
1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
InChIKey :
OJQMKCBWYCWFPU-UHFFFAOYSA-N
Solubility :
Soluble in DMSO
Appearance :
Solid powder
Application :
prostacyclin receptor agonist
Storage : Store at -20 °C
Synonyms :
MRE-269; MRE269; MRE 269; ACT-333679; ACT 333679; ACT333679. [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid; 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-acetic Acid;

More details are to be found here

Description :
MRE-269 is an orally available and long-acting prostacyclin receptor agonist prodrug used for the treatment of pulmonary arterial hypertension.

• Molecular Weight :419.5
• Purity :≥98%

Molecular Formula :
C25H29N3O3
Canonical SMILES :
OC(=O)COCCCCN(C(C)C)c1cnc(c2ccccc2)c(n1)c1ccccc1
InChI :
1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
InChIKey :
OJQMKCBWYCWFPU-UHFFFAOYSA-N
Solubility :
Soluble in DMSO
Appearance :
Solid powder
Application :
prostacyclin receptor agonist
Storage : Store at -20 °C
Synonyms :
MRE-269; MRE269; MRE 269; ACT-333679; ACT 333679; ACT333679. [4-[(5,6-diphenylpyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid; 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-acetic Acid;

More details are to be found here